JP2012519676A5 - - Google Patents

Download PDF

Info

Publication number
JP2012519676A5
JP2012519676A5 JP2011552505A JP2011552505A JP2012519676A5 JP 2012519676 A5 JP2012519676 A5 JP 2012519676A5 JP 2011552505 A JP2011552505 A JP 2011552505A JP 2011552505 A JP2011552505 A JP 2011552505A JP 2012519676 A5 JP2012519676 A5 JP 2012519676A5
Authority
JP
Japan
Prior art keywords
polypeptide
spinal cord
cord injury
protein kinase
kinase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011552505A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012519676A (ja
JP5670921B2 (ja
Filing date
Publication date
Priority claimed from GBGB0903913.2A external-priority patent/GB0903913D0/en
Application filed filed Critical
Publication of JP2012519676A publication Critical patent/JP2012519676A/ja
Publication of JP2012519676A5 publication Critical patent/JP2012519676A5/ja
Application granted granted Critical
Publication of JP5670921B2 publication Critical patent/JP5670921B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011552505A 2009-03-06 2010-03-05 神経突起伸長阻害の軽減のためのプロテインキナーゼａ及び／又はカゼインキナーゼｉｉ Expired - Fee Related JP5670921B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0903913.2 2009-03-06
GBGB0903913.2A GB0903913D0 (en) 2009-03-06 2009-03-06 Compositions and methods
PCT/GB2010/000391 WO2010100428A2 (en) 2009-03-06 2010-03-05 Compositions and methods

Publications (3)

Publication Number Publication Date
JP2012519676A JP2012519676A (ja) 2012-08-30
JP2012519676A5 true JP2012519676A5 (enExample) 2013-04-11
JP5670921B2 JP5670921B2 (ja) 2015-02-18

Family

ID=40600640

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011552505A Expired - Fee Related JP5670921B2 (ja) 2009-03-06 2010-03-05 神経突起伸長阻害の軽減のためのプロテインキナーゼａ及び／又はカゼインキナーゼｉｉ

Country Status (10)

Country Link
US (1) US9089565B2 (enExample)
EP (1) EP2403515B1 (enExample)
JP (1) JP5670921B2 (enExample)
CN (1) CN102341117B (enExample)
AU (1) AU2010219463A1 (enExample)
CA (1) CA2750911A1 (enExample)
DK (1) DK2403515T3 (enExample)
ES (1) ES2493619T3 (enExample)
GB (1) GB0903913D0 (enExample)
WO (1) WO2010100428A2 (enExample)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3214099A (en) 1998-04-03 1999-10-25 Curagen Corporation Lyst protein complexes and lyst interacting proteins
US6903187B1 (en) * 2000-07-21 2005-06-07 Allergan, Inc. Leucine-based motif and clostridial neurotoxins
JP2005508631A (ja) * 2001-07-17 2005-04-07 インサイト・ゲノミックス・インコーポレイテッド 受容体および膜結合タンパク質
JP2003093056A (ja) 2001-09-26 2003-04-02 Japan Science & Technology Corp ｐ５３のＳｅｒ４６をリン酸化する酵素
JP2007526440A (ja) 2003-06-03 2007-09-13 バイエル・ヘルスケア・エルエルシー 携帯型医療診断装置
GB0314943D0 (en) * 2003-06-25 2003-07-30 Proteome Sciences Plc Screening methods
CN1849132A (zh) * 2003-09-10 2006-10-18 伦敦大学国王学院 调节神经元生长的化合物以及它们的用途
CA2549000A1 (en) * 2003-12-16 2005-06-30 Children's Medical Center Corporation Method for treating neurological disorders
US20050214288A1 (en) * 2004-03-26 2005-09-29 Human Genome Sciences, Inc. Antibodies against Nogo receptor
EP1789070B1 (en) 2004-08-03 2012-10-24 Biogen Idec MA Inc. Taj in neuronal function
US7414637B2 (en) * 2004-09-10 2008-08-19 Telmap Ltd. Placement of map labels
CA2684321A1 (en) 2007-03-21 2008-09-25 Effat Emamian Compositions comprising pkac fragments and uses thereof for inhibiting akt1, p70s6k or abl activity

Similar Documents

Publication Publication Date Title
ZA202004764B (en) Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
MX2021002321A (es) Nuevos metodos.
EP3747457A3 (en) Factor 1 protein, factor 2 protein and inhibitors thereof for use in treating or preventing diseases
JP2016509011A5 (enExample)
WO2017087608A8 (en) Modulators of ror-gamma
PH12016501394A1 (en) Compounds for treating patients with ros1 mutant cancer cells
WO2012080729A3 (en) Casein kinase 1delta (ck1delta) inhibitors and their use in the treatment of neurodegenerative diseases such as tauopathies
MY199967A (en) Combinations of lsd1 inhibitors for use in the treatment of solid tumors
MX2023010328A (es) Composiciones de medicamentos a base de peptido de colageno y metodos y dispositivos para su produccion y uso.
NZ611108A (en) Methods of treating fgf21-associated disorders
HK1210422A1 (en) Compositions and methods for treating cutaneous scarring
JP2014530220A5 (enExample)
MY157564A (en) Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract
HK1206726A1 (en) Imidazotriazinone compounds
JP2014050390A5 (enExample)
WO2007135026A3 (de) Substituierte pteridine als therapeutika
RU2016108808A (ru) Терапевтическое применение vegf-c и ccbe1
PH12014502623A1 (en) Difluoro-hexahydro-cyclopentaoxazinyls and difluoro-hexahydro-benzooxazinyls as bace1 inhibitors
MX2020010807A (es) Peptidos promotores del crecimiento y usos de los mismos.
CO6592047A2 (es) Formulación tópica oftálmica de péptidos
WO2016004413A3 (en) Gls1 inhibitors for treating disease
WO2016015798A9 (en) Orodispersible film composition comprising enalapril for the treatment of hypertension in a pediatric population
MX2016005976A (es) Formulaciones de tripeptido liofilizado estables en almacenamiento.
WO2016025671A3 (en) Treatment of sleep apnea with a combination of a carbonic anhydrase inhibitor and an aldosterone antagonist
IL202206A0 (en) Substituted (oxazolidinon-5-yl-methyl) -2-thiophene-carboxamides and use thereof in the field of blood coagulation